Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Increased to Strong-Buy at HC Wainwright

Key Points

• HC Wainwright has upgraded Zentalis Pharmaceuticals (NASDAQ:ZNTL) to a "strong-buy" rating, indicating increased confidence in the company's stock.
• Several analysts have differing opinions on Zentalis, with a consensus average rating of "Moderate Buy" and a target price of $8.20.
• Zentalis Pharmaceuticals has a market cap of $103.61 million and reported an earnings per share of ($0.37), beating the consensus estimate.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) was upgraded by investment analysts at HC Wainwright to a "strong-buy" rating in a research report issued on Thursday,Zacks.com reports.

Other equities analysts have also issued reports about the company. Wedbush reiterated a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Wells Fargo & Company reduced their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $8.20.

Zentalis Pharmaceuticals Stock Up 0.7%

Shares of Zentalis Pharmaceuticals stock traded up $0.01 during trading on Thursday, hitting $1.41. 588,657 shares of the stock traded hands, compared to its average volume of 1,242,152. The stock has a market cap of $101.72 million, a price-to-earnings ratio of -0.62 and a beta of 1.71. The firm's fifty day moving average is $1.38 and its 200-day moving average is $1.55. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.19. On average, analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its holdings in Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after buying an additional 2,111,951 shares during the period. Acadian Asset Management LLC lifted its holdings in Zentalis Pharmaceuticals by 150.6% in the 1st quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company's stock worth $4,244,000 after buying an additional 1,606,802 shares during the period. Integral Health Asset Management LLC purchased a new stake in Zentalis Pharmaceuticals in the 4th quarter worth approximately $3,182,000. Almitas Capital LLC lifted its holdings in Zentalis Pharmaceuticals by 69.3% in the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock worth $4,929,000 after buying an additional 665,968 shares during the period. Finally, Peapod Lane Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the 1st quarter worth approximately $888,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.